Discontinued — last reported Q1 '26
Alliance revenue - Lenvima — Sales
Merck & Co. Alliance revenue - Lenvima — Sales decreased by 52.9% to $256.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 50.4%, from $516.00M to $256.00M. Over 4 years (FY 2021 to FY 2025), Alliance revenue - Lenvima — Sales shows an upward trend with a 10.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher sales indicate strong market adoption and product growth, which is a primary driver of company revenue.
Detailed definition
The total gross or net revenue generated from the sale of the specific product line within the alliance framework. This...
Peer comparison
Standard top-line revenue metric for product-specific performance analysis across all industries.
mrk_segment_alliance_revenue_lenvima_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $362.00M | $376.00M | $411.00M | $454.00M | $462.00M | $404.00M | $432.00M | $464.00M | $484.00M | $520.00M | $452.00M | $510.00M | $499.00M | $502.00M | $509.00M | $516.00M | $531.00M | $516.00M | $543.00M | $256.00M |
| QoQ Change | — | +3.9% | +9.3% | +10.5% | +1.8% | -12.6% | +6.9% | +7.4% | +4.3% | +7.4% | -13.1% | +12.8% | -2.2% | +0.6% | +1.4% | +1.4% | +2.9% | -2.8% | +5.2% | -52.9% |
| YoY Change | — | — | — | — | +27.6% | +7.4% | +5.1% | +2.2% | +4.8% | +28.7% | +4.6% | +9.9% | +3.1% | -3.5% | +12.6% | +1.2% | +6.4% | +2.8% | +6.7% | -50.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s alliance revenue - lenvima — sales?
- Merck & Co. (MRK) reported alliance revenue - lenvima — sales of $256.00M in Q1 2026.
- How has Merck & Co.'s alliance revenue - lenvima — sales changed year-over-year?
- Merck & Co.'s alliance revenue - lenvima — sales decreased by 50.4% year-over-year, from $516.00M to $256.00M.
- What is the long-term trend for Merck & Co.'s alliance revenue - lenvima — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s alliance revenue - lenvima — sales has grown at a 10.6% compound annual growth rate (CAGR), from $1.41B to $2.11B.
- What does alliance revenue - lenvima — sales mean?
- The total revenue generated from sales of the specific product.